NZ563845A - RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic - Google Patents

RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic

Info

Publication number
NZ563845A
NZ563845A NZ563845A NZ56384506A NZ563845A NZ 563845 A NZ563845 A NZ 563845A NZ 563845 A NZ563845 A NZ 563845A NZ 56384506 A NZ56384506 A NZ 56384506A NZ 563845 A NZ563845 A NZ 563845A
Authority
NZ
New Zealand
Prior art keywords
influenza
gene
segment
sequences against
rnai sequences
Prior art date
Application number
NZ563845A
Other languages
English (en)
Inventor
Qing Ge
Mukesh Kumar
James Anthony Mcswiggen
Original Assignee
Marina Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marina Biotech Inc filed Critical Marina Biotech Inc
Publication of NZ563845A publication Critical patent/NZ563845A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ563845A 2005-04-08 2006-04-07 RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic NZ563845A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66994205P 2005-04-08 2005-04-08
PCT/US2006/013374 WO2006110688A2 (en) 2005-04-08 2006-04-07 Rnai therapeutic for respiratory virus infection

Publications (1)

Publication Number Publication Date
NZ563845A true NZ563845A (en) 2010-09-30

Family

ID=37087607

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ563845A NZ563845A (en) 2005-04-08 2006-04-07 RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic

Country Status (10)

Country Link
US (1) US20100254945A1 (enExample)
EP (1) EP1874802A2 (enExample)
JP (1) JP2008535496A (enExample)
KR (1) KR20070118703A (enExample)
CN (1) CN101184839A (enExample)
AU (1) AU2006235364A1 (enExample)
CA (1) CA2603842A1 (enExample)
NO (1) NO20075655L (enExample)
NZ (1) NZ563845A (enExample)
WO (1) WO2006110688A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
CA2602797A1 (en) * 2005-03-31 2007-02-15 Ronen Kahana Creating poultry and other animals resistant to viral disease
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
EP2146575A4 (en) * 2007-04-12 2010-11-24 Alnylam Pharmaceuticals Inc INFLUENZA POLYNUCLEOTIDES, EXPRESSION CONSTRUCTS, COMPOSITIONS AND METHOD FOR THEIR USE
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
AU2008251037A1 (en) * 2007-05-15 2008-11-20 Johnson & Johnson Research Pty Limited Suppression of viruses involved in respiratory infection or disease
EP2527445A3 (en) * 2007-05-16 2013-02-20 MAT Malta Advanced Technologies Limited Treatment and prevention of influenza
US20100273156A1 (en) * 2007-05-31 2010-10-28 Becton, Dickinson And Company Sequences and methods for detecting influenza a and influenza b virus
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
EP2631291B1 (en) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
KR20140027211A (ko) 2011-04-04 2014-03-06 유니버시티 오브 아이오와 리써치 파운데이션 백신 면역원성의 개선 방법
US9328347B2 (en) 2011-07-18 2016-05-03 Oregon Health & Science University siRNA useful in the treatment of flavivirus infection
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
WO2013103434A1 (en) * 2011-10-19 2013-07-11 Harrisvaccines, Inc. Methods and compositions to protect aquatic invertebrates from disease
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
WO2014138792A1 (en) * 2013-03-14 2014-09-18 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
WO2017085550A1 (en) 2015-11-16 2017-05-26 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
US10358648B2 (en) 2016-02-02 2019-07-23 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
EP3423107A4 (en) * 2016-03-02 2020-01-15 The Board of Trustees of the Leland Stanford Junior University PAN-GENOTYPICAL AGENTS AGAINST INFLUENZA-B VIRUS AND METHOD FOR USE THEREOF
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
KR102339886B1 (ko) 2016-04-11 2021-12-17 올릭스 주식회사 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
US11952631B2 (en) * 2017-10-09 2024-04-09 Medizinische Hochschule Hannover Diagnostics and therapy for human respiratory syncytial virus
US11739350B2 (en) 2018-04-10 2023-08-29 Ottawa Hospital Research Institute MicroRNA-based compositions and methods used in disease treatment
US11702709B2 (en) * 2021-02-09 2023-07-18 Pathogendx, Inc. Combinatorial microarray assay for clade variant detection
CN115120608A (zh) * 2021-03-26 2022-09-30 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
EP4562157A1 (en) * 2022-07-28 2025-06-04 New York University Targeting long non-coding rna chromr in interferon-mediated inflammation in humans
EP4527927A1 (en) 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses
CN118800477B (zh) * 2024-07-11 2025-05-02 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5011769A (en) 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5573907A (en) 1990-01-26 1996-11-12 Abbott Laboratories Detecting and amplifying target nucleic acids using exonucleolytic activity
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) * 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
ATE247716T1 (de) 1994-02-07 2003-09-15 Beckman Coulter Inc Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse
JP3898228B2 (ja) * 1996-04-12 2007-03-28 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク 検出プローブ、キット及びアッセイ
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US20030087851A1 (en) * 1999-01-20 2003-05-08 Biozak, Inc. Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide
US6277607B1 (en) * 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
EP1081496A1 (en) * 1999-08-31 2001-03-07 Becton, Dickinson and Company Flow-through assay for visually detecting the presence of influenza A and B
US20040137471A1 (en) * 2002-09-18 2004-07-15 Timothy Vickers Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
EP1658304A4 (en) * 2002-09-28 2009-01-14 Massachusetts Inst Technology THERAPY ANTIGRIPPALE
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US9486070B2 (en) 2012-10-10 2016-11-08 Stirworks Inc. Height-adjustable support surface and system for encouraging human movement and promoting wellness

Also Published As

Publication number Publication date
CA2603842A1 (en) 2006-10-19
KR20070118703A (ko) 2007-12-17
CN101184839A (zh) 2008-05-21
WO2006110688A2 (en) 2006-10-19
JP2008535496A (ja) 2008-09-04
EP1874802A2 (en) 2008-01-09
WO2006110688A3 (en) 2008-01-10
WO2006110688A9 (en) 2007-03-15
AU2006235364A1 (en) 2006-10-19
NO20075655L (no) 2007-11-13
US20100254945A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
MX2010004452A (es) Acido ribonucleico de doble cadena modificado con lipidos que tienen un potente efecto de interferencia de acido ribonucleico.
SG171676A1 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
NZ592867A (en) Compositions and methods for inhibiting expression of transthyretin
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
WO2008036933A3 (en) Compositions and methods for inhibiting expression of the hamp gene
NZ587060A (en) Rna interference for the treatment of heart failure
NZ593618A (en) Gnaq targeted dsrna compositions and methods for inhibiting expression
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
WO2006121464A3 (en) Compositions for treating respiratory viral infections and their use
WO2007137156A8 (en) Rnai modulation of aha and therapeutic uses thereof
NZ597601A (en) Treatment and prevention of influenza
WO2007127919A3 (en) Compositions and methods for inhibiting expression of a gene from the jc virus
ATE522607T1 (de) Sense-oligonukleotid mit fähigkeit zur kontrolle der expression von inos sowie dieses umfassende zusammensetzung
WO2009074970A3 (en) Means for delivery of nucleic acids active for gene silencing using synthetic polymers
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2012156817A3 (en) Method for treating non-small cell lung cancer
WO2006032041A3 (en) Compositions and methods for inhibiting expression of anti-apoptotic genes
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2005112636A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES
NZ609440A (en) Preventative or therapeutic agent for fibrosis
WO2008001219A3 (en) Cancer therapy using bcl-xl-specific sina

Legal Events

Date Code Title Description
RENP Pct: late entry into national phase requested

Effective date: 20071128

LENP Pct: late entry into national phase granted

Effective date: 20071128

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed